# US 2010/0168197 A1 · Muscarinic receptor antagonists

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0168197 A1
- Document ID: US20100168197A1
- Status: Published application
- Kind: A1
- Application number: 12/528,987
- Filed: 2008-02-27
- Published: 2010-07-01
- Earliest claimed: 2007-02-28
- Inventors: Naresh Kumar; Jaskiran Kaur; Shelly Aeron; Abhijit Ray; Suman Gupta; Shivani Malhotra; Raj Kumar Shirumalla
- Web page: https://patentgrep.com/patent/US20100168197A1

## CPC

- C07D 235/08: Radicals containing only hydrogen and carbon atoms
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 13/00: Drugs for disorders of the urinary system
- C07D 233/54: having two double bonds between ring members or between ring members and non-ring members
- C07D 409/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

This present invention generally relates to muscarinic receptor antagonists, which are useful, among other uses, for the treatment of various diseases of the respiratory, urinary and gastrointestinal systems mediated through muscarinic receptors. The invention also relates to the process for the preparation of disclosed compounds, pharmaceutical compositions containing the disclosed compounds, and the methods for treating diseases mediated through muscarinic receptors.

## Claims

### Claim 1

Compounds having the structure of Formula I:
and its pharmaceutically accepted salts, pharmaceutically acceptable solvates, enantiomers, diastereomers, polymorphs or N-oxides wherein
represents a single bond when G is —OH and double bond when G is —O;
R1 and R2 are independently selected from hydrogen, alkyl, alkenyl, alkynyl, aralkyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, heterocyclylalkyl or heteroarylalkyl;
R3 is selected from the group selected from hydrogen, hydroxy, alkoxy, alkenyloxy or alkynyloxy;
X is selected from oxygen, —NH, —NR (wherein R is alkyl, alkenyl, alkenyl, alkynyl or aryl), sulphur or no atom;
Het is heterocyclyl or heteroaryl;
n is an integer from 1 to 6;
with the proviso that when R1 and R2 are phenyl, R3 is hydroxy and X is no atom, then Het cannot be a saturated heterocyclyl group.

### Claim 2

A compound selected from the group consisting of
3-(4-Bromobenzyl)-1-[2-({(2R)-2-[(1R)-3,3-difluorocyclohexyl]-2-hydroxy-2-phenylacetyl}oxy)ethyl]-2-methyl-1H-imidazol-3-ium bromide (Compound No. 1);
1-[2-({(2R)-2-[(1R)-3,3-Difluorocyclohexyl]-2-hydroxy-2-phenylacetyl}oxy)ethyl]-2,3-dimethyl-1H-imidazol-3-ium iodide (Compound No. 2);
1-(2-{[Cycloheptyl(hydroxy)phenylacetyl]oxy}ethyl)-2-methyl-3-(4-methylbenzyl)-1H-imidazol-3-ium bromide (Compound No. 3);
1-[2-({(2R)-2-[(1R)-3,3-Difluorocyclopentyl]-2-hydroxy-2-phenylacetyl}oxy)ethyl]-2-methyl-3-(4-methylbenzyl)-1H-imidazol-3-ium bromide (Compound No. 4);
1-[3-({(2R)-2-[(1R)-3,3-Difluorocyclohexyl]-2-hydroxy-2-phenylacetyl}oxy)propyl]-2,3-dimethyl-1H-imidazol-3-ium iodide (Compound No. 5);
1-(3-{[Cycloheptyl(hydroxy)phenylacetyl]oxy}propyl)-2,3-dimethyl-1H-imidazol-3-ium iodide (Compound No. 6);
1-(3-{[Cycloheptyl(hydroxy)phenylacetyl]oxy}propyl)-2-methyl-3-(4-methylbenzyl)-1H-imidazol-3-ium bromide (Compound No. 7);
3-(4-Bromobenzyl)-1-(3-{[cycloheptyl(hydroxy)phenylacetyl]oxy}propyl)-2-methyl-1H-imidazol-3-ium bromide (Compound No. 8);
3-(4-Bromobenzyl)-1-[3-({(2R)-2-[(1R)-3,3-difluorocyclohexyl]-2-hydroxy-2-phenylacetyl}oxy)propyl]-2-methyl-1H-imidazol-3-ium bromide (Compound No. 9);
1-[2-({(2R)-2-[(1R)-3,3-Difluorocyclohexyl]-2-hydroxy-2-phenylacetyl}oxy)ethyl]-2-methyl-3-(4-methylbenzyl)-1H-imidazol-3-ium bromide (Compound No. 10);
1-[2-({(2R)-2-[(1R)-3,3-Difluorocyclohexyl]-2-hydroxy-2-phenylacetyl}oxy)ethyl]-3-(4-fluorobenzyl)-2-methyl-1H-imidazol-3-ium bromide (Compound No. 11);
3-[2-(1,3-Benzodioxol-5-yl)ethyl]-1-(3-[cycloheptyl(hydroxy)phenylacetyl]oxy}propyl)-2-methyl-1H-imidazol-3-ium bromide (Compound No. 12);
1-[3-({(2R)-2-[(1R)-3,3-Difluorocyclopentyl]-2-hydroxy-2-phenylacetyl}oxy)propyl]-3-(4-fluorobenzyl)-2-methyl-1H-imidazol-3-ium (Compound No. 13);
1-(3-{[Cycloheptyl(hydroxy)phenylacetyl]oxy}propyl)-3-(4-fluorobenzyl)-2-methyl-1H-imidazol-3-ium bromide (Compound No. 14);
3-(4-Bromobenzyl)-1-[2-({(2R)-2-[(1S)-3,3-difluorocyclohexyl]-2-hydroxy-2-phenylacetyl}oxy)ethyl]-2-methyl-1H-imidazol-3-ium bromide (Compound No. 15);
3-(4-Fluorobenzyl)-1-[2-({(2R)-2-[(1S)-3,3-difluorocyclohexyl]-2-hydroxy-2-phenylacetyl}oxy)ethyl]-2-methyl-1H-imidazol-3-ium bromide (Compound No. 16);
3-Benzyl-1-[2-({(2R)-2-[(1R)-3,3-difluorocyclopentyl]-2-hydroxy-2-phenylacetyl}oxy)ethyl]-2-methyl-1H-imidazol-3-ium chloride (Compound No. 17);
3-Benzyl-1-[2-({(2R)-2-[(1S)-3,3-difluorocyclohexyl]-2-hydroxy-2-phenylacetyl}oxy)ethyl]-2-methyl-1H-imidazol-3-ium bromide (Compound No. 18);
1-[2-({(2R)-2-[(1R)-3,3-Difluorocyclopentyl]-2-hydroxy-2-phenylacetyl}oxy)ethyl]-2,3-dimethyl-1H-imidazol-3-ium bromide (Compound No. 19);
1-[3-({(2R)-2-[(1R)-3,3-Difluorocyclopentyl]-2-hydroxy-2-phenylacetyl}oxy)propyl]-3-isopropyl-2-methyl-1H-imidazol-3-ium bromide (Compound No. 20);
1-[3-({(2R)-2-[(1R)-3,3-Difluorocyclopentyl]-2-hydroxy-2-phenylacetyl}oxy)propyl]-3-ethyl-2-methyl-1H-imidazol-3-ium iodide (Compound No. 21);
3-(Cyclopropylmethyl)-1-[3-({(2R)-2-[(1R)-3,3-difluorocyclopentyl]-2-hydroxy-2-phenylacetyl]oxy)propyl}-2-methyl-1H-imidazol-3-ium bromide (Compound No. 22);
3-(Cyclohexylmethyl)-1-[3-({(2R)-2-[(1R)-3,3-difluorocyclopentyl]-2-hydroxy-2-phenylacetyl}oxy)propyl]-2-methyl-1H-imidazol-3-ium bromide (Compound No. 23);
1-[3-({(2R)-2-[(1R)-3,3-Difluorocyclopentyl]-2-hydroxy-2-phenylacetyl}oxy)propyl]-2-methyl-3-[4-(trifluoromethyl)benzyl]-1H-imidazol-3-ium chloride (Compound No. 24);
3-(4-Chlorobenzyl)-1-[3-({(2R)-2-[(1R)-3,3-difluorocyclopentyl]-2-hydroxy-2-phenylacetyl}oxy)propyl]-2-methyl-1H-imidazol-3-ium chloride (Compound No. 25);
3-(3-Bromobenzyl)-1-[3-({(2R)-2-[(1R)-3,3-difluorocyclopentyl]-2-hydroxy-2-phenylacetyl]oxy)propyl}-2-methyl-1H-imidazol-3-ium bromide (Compound No. 26);
1-[3-({(2R)-2-[(1R)-3,3-Difluorocyclopentyl]-2-hydroxy-2-phenylacetyl}oxy)propyl]-3-(4-fluorobenzyl)-2-methyl-1H-imidazol-3-ium chloride (Compound No. 27);
3-Benzyl-1-[3-({(2R)-2-[(1R)-3,3-difluorocyclopentyl]-2-hydroxy-2-phenylacetyl}oxy)propyl]-2-methyl-1H-imidazol-3-ium chloride (Compound No. 28);
1-[3-({(2R)-2-[(1R)-3,3-Difluorocyclopentyl]-2-hydroxy-2-phenylacetyl}oxy)propyl]-2-methyl-3-(2-phenylethyl)-1H-imidazol-3-ium bromide (Compound No. 29);
1-[3-({(2R)-2-[(1R)-3,3-Difluorocyclopentyl]-2-hydroxy-2-phenylacetyl}oxy)propyl]-2,3-dimethyl-1H-imidazol-3-ium bromide (Compound No. 30);
1-[3-({(2R)-2-[(1R)-3,3-Difluorocyclohexyl]-2-hydroxy-2-phenylacetyl}oxy)propyl]-3-(4-fluorobenzyl)-2-methyl-1H-imidazol-3-ium bromide (Compound No. 31);
3-Benzyl-1-{3-[2-cycloheptyl(hydroxy)phenylacetoxy]propyl}-2-methyl-1H-imidazol-3-ium chloride (Compound No. 32);
1-(3-{[2-Cycloheptyl(hydroxy)phenylacetyl]oxy}propyl)-2,3-dimethyl-1H-imidazol-3-ium bromide (Compound No. 33);
1-[44 {(2R)-2-[(1R)-3,3-Difluorocyclopentyl]-2-hydroxy-2-phenylacetyl}oxy)butyl]-2,3-dimethyl-1H-imidazol-3-ium bromide (Compound No. 34);
3-Benzyl-1-[44 {(2R)-2-[(1R)-3,3-difluorocyclopentyl]-2-hydroxy-2-phenylacetyl}oxy)butyl]-2-methyl-1H-imidazol-3-ium bromide (Compound No. 35);
3-Benzyl-1-[2-({(2R)-2-[(1R)-3,3-difluorocyclohexyl]-2-hydroxy-2-phenylacetyl}oxy)ethyl]-2-methyl-1H-imidazol-3-ium bromide (Compound No. 36);
3-Benzyl-1-[3-({(2R)-2-[(1R)-3,3-difluorocyclohexyl]-2-hydroxy-2-phenylacetyl}oxy)propyl]-2-methyl-1H-imidazol-3-ium chloride (Compound No. 37);
1-[44 {(2R)-2-[(1R)-3,3-Difluorocyclohexyl]-2-hydroxy-2-phenylacetyl}oxy)butyl]-2,3-dimethyl-1H-imidazol-3-ium bromide (Compound No. 38);
3-Benzyl-1-[44 {(2R)-2-[(1R)-3,3-difluorocyclohexyl]-2-hydroxy-2-phenylacetyl}oxy)butyl]-2-methyl-1H-imidazol-3-ium bromide (Compound No. 39);
3-(4-tert-Butylbenzyl)-1-[2-({(2R)-2-[(1R)-3,3-difluorocyclopentyl]-2-hydroxy-2-phenylacetyl}oxy)ethyl]-2-methyl-1H-imidazol-3-ium bromide (Compound No. 40);
3-(Biphenyl-4-ylmethyl)-1-[2-({(2R)-2-[(1R)-3,3-difluorocyclopentyl]-2-hydroxy-2-phenylacetyl}oxy)ethyl]-2-methyl-1H-imidazol-3-ium bromide (Compound No. 41);
3-(2,5-Difluorobenzyl)-1-[2-({(2R)-2-[(1R)-3,3-difluorocyclopentyl]-2-hydroxy-2-phenylacetyl}oxy)ethyl]-2-methyl-1H-imidazol-3-ium bromide (Compound No. 42);
3-(2,4-Difluorobenzyl)-1-[2-({(2R)-2-[(1R)-3,3-difluorocyclopentyl]-2-hydroxy-2-phenylacetyl}oxy)ethyl]-2-methyl-1H-imidazol-3-ium bromide (Compound No. 43);
3-(3,5-Difluorobenzyl)-1-[2-({(2R)-2-[(1R)-3,3-difluorocyclopentyl]-2-hydroxy-2-phenylacetyl}oxy)ethyl]-2-methyl-1H-imidazol-3-ium bromide (Compound No. 44);
3-(3,4-Difluorobenzyl)-1-[2-({(2R)-2-[(1R)-3,3-difluorocyclopentyl]-2-hydroxy-2-phenylacetyl}oxy)ethyl]-2-methyl-1H-imidazol-3-ium bromide (Compound No. 45);
1-{3-[2-Cyclopentyl(hydroxy)phenylacetoxy]propyl}-2-methyl-3-(pyridin-4-ylmethyl)-1H-imidazol-3-ium bromide (Compound No. 46);
1-[3-({(2R)-2-[(1R)-3,3-Difluorocyclopentyl]-2-hydroxy-2-phenylacetyl}oxy)propyl]-3-(1-ethylpropyl)-2-methyl-1H-imidazol-3-ium bromide (Compound No. 47);
3-(1,3-Benzodioxol-5-ylmethyl)-1-[3-({(2R)-2-[(1R)-3,3-difluorocyclopentyl]-2-hydroxy-2-phenylacetyl}oxy)propyl]-2-methyl-1H-imidazol-3-ium bromide (Compound No. 48);
1-[3-({(2R)-2-[(1R)-3,3-Difluorocyclopentyl]-2-hydroxy-2-phenylacetyl}oxy)propyl]-2-methyl-3-propyl-1H-imidazol-3-ium bromide (Compound No. 49);
1-[3-({(2R)-2-[(1R)-3,3-Difluorocyclopentyl]-2-hydroxy-2-phenylacetyl}oxy)propyl]-3-isobutyl-2-methyl-1H-imidazol-3-ium bromide (Compound No. 50);
3-Butyl-1-[3-({(2R)-2-[(1R)-3,3-difluorocyclopentyl]-2-hydroxy-2-phenylacetyl}oxy)propyl]-2-methyl-1H-imidazol-3-ium bromide (Compound No. 51);
1-{2-[2-Hydroxy(phenyl)-2-thienylacetoxy]ethyl}-2-methyl-3-(2-phenylethyl)-1H-imidazol-3-ium bromide (Compound No. 52);
3-(Cyclopropylmethyl)-1-{2-[2-hydroxy(phenyl)-2-thienylacetoxy]ethyl}-2-methyl-1H-imidazol-3-ium bromide (Compound No. 53);
3-Benzyl-1-{2-[2-hydroxy(phenyl)-2-thienylacetoxy]ethyl}-2-methyl-1H-imidazol-3-ium bromide (Compound No. 54);
1-{2-[2-Hydroxy(phenyl)-2-thienylacetoxy]ethyl}-2,3-dimethyl-1H-imidazol-3-ium bromide (Compound No. 55);
3-(Cyclopropylmethyl)-1-(2-{2-hydroxy[bis(3-methylphenyl)]acetoxy}ethyl)-2-methyl-1H-imidazol-3-ium bromide (Compound No. 56);
1-(2-{2-Hydroxy[bis(3-methylphenyl)]acetoxy}ethyl)-2,3-dimethyl-1H-imidazol-3-ium bromide (Compound No. 57);
3-Benzyl-1-(2-{2-hydroxy[bis(3-methylphenyl)]acetoxy}ethyl)-2-methyl-1H-imidazol-3-ium bromide (Compound No. 58);
1-{2-[2,2-Bis(4-fluorophenyl)(hydroxy)acetoxy]ethyl}-2,3-dimethyl-1H-imidazol-3-ium bromide (Compound No. 59);
3-Benzyl-1-{2-[2,2-h]s (4-fluorophenyl)(hydroxy)acetoxy]ethyl}-2-methyl-1H-imidazol-3-ium bromide (Compound No. 60);
1-{2-[2,2-Bis(4-fluorophenyl)(hydroxy)acetoxy]ethyl}-3-(cyclopropylmethyl)-2-methyl-1H-imidazol-3-ium bromide (Compound No. 61);
3-Benzyl-1-{3-[2,2-bis(4-fluorophenyl)(hydroxy)acetoxy]propyl}-2-methyl-1H-imidazol-3-ium bromide (Compound No. 62);
1-{3-[2,2-bis(4-Fluorophenyl)(hydroxy)acetoxy]propyl}-3-(cyclopropylmethyl)-2-methyl-1H-imidazol-3-ium bromide (Compound No. 63);
1-{3-[2,2-bis(4-Fluorophenyl)(hydroxy)acetoxy]propyl}-3-ethyl-2-methyl-1H-imidazol-3-ium bromide (Compound No. 64);
1-[3-({(2R)-2-[(1R)-3,3-Difluorocyclopentyl]-2-hydroxy-2-phenylacetyl}oxy)propyl]-2-methyl-3-(3-phenoxypropyl)-1H-imidazol-3-ium bromide (Compound No. 65);
1-[3-({(2R)-2-[(1R)-3,3-Difluorocyclohexyl]-2-hydroxy-2-phenylacetyl}oxy)propyl]-2-methyl-3-(3-phenoxypropyl)-1H-imidazol-3-ium bromide (Compound No. 66);
1-[3-({(2R)-2-[(1R)-3,3-Difluorocyclohexyl]-2-hydroxy-2-phenylacetyl}oxy)propyl]-2-methyl-3-propyl-1H-imidazol-3-ium bromide (Compound No. 67);
1-[3-({(2R)-2-[(1R)-3,3-Difluorocyclohexyl]-2-hydroxy-2-phenylacetyl}oxy)propyl]-3-isopropyl-2-methyl-1H-imidazol-3-ium bromide (Compound No. 68);
3-(Cyclopropylmethyl)-1-[3-({(2R)-2-[(1R)-3,3-difluorocyclohexyl]-2-hydroxy-2-phenylacetyl]oxy)propyl}-2-methyl-1H-imidazol-3-ium bromide (Compound No. 69);
3-(Cyclohexylmethyl)-1-[3-({(2R)-2-[(1R)-3,3-difluorocyclohexyl]-2-hydroxy-2-phenylacetyl]oxy)propyl}-2-methyl-1H-imidazol-3-ium bromide (Compound No. 70);
1-[3-({(2R)-2-[(1R)-3,3-Difluorocyclohexyl]-2-hydroxy-2-phenylacetyl}oxy)propyl]-2-methyl-3-(2-phenylethyl)-1H-imidazol-3-ium bromide (Compound No. 71);
1-[3-({(2R)-2-[(1R)-3,3-Difluorocyclohexyl]-2-hydroxy-2-phenylacetyl}oxy)propyl]-2,3-dimethyl-1H-imidazol-3-ium bromide (Compound No. 72);
1-{3-[2,2-bis(4-Fluorophenyl)(hydroxy)acetoxy]propyl}-2,3-dimethyl-1H-imidazol-3-ium bromide (Compound No. 73);
3-(4-Bromobenzyl)-1-(3-{2-hydroxy {bis(3-methylphenyl)]acetoxy}propyl)-2-methyl-1H-imidazol-3-ium bromide (Compound No. 74);
3-Benzyl-1-(3-{2-hydroxy {bis(3-methylphenyl)]acetoxy}propyl)-2-methyl-1H-imidazol-3-ium bromide (Compound No. 75);
3-(Cyclopropylmethyl)-1-(3-{2-hydroxy[bis(3-methylphenyl)]acetoxy}propyl)-2-methyl-1H-imidazol-3-ium bromide (Compound No. 76);
3-Ethyl-1-(3-{2-hydroxy[bis(3-methylphenyl)]acetoxy}propyl)-2-methyl-1H-imidazol-3-ium bromide (Compound No. 77);
1-(3-{2-Hydroxy[bis(3-methylphenyl)]acetoxy}propyl)-2,3-dimethyl-1H-imidazol-3-ium bromide (Compound No. 78);
3-(4-Bromobenzyl)-1-{3-[2-hydroxy(phenyl)-2-thienylacetoxy]propyl}-2-methyl-1H-imidazol-3-ium bromide (Compound No. 79);
3-Benzyl-1-{3-[2-hydroxy(phenyl)-2-thienylacetoxy]propyl}-2-methyl-1H-imidazol-3-ium bromide (Compound No. 80);
3-(Cyclopropylmethyl)-1-{3-[2-hydroxy(phenyl)-2-thienylacetoxy]propyl}-2-methyl-1H-imidazol-3-ium bromide (Compound No. 81);
3-Ethyl-1-{3-[2-hydroxy(phenyl)-2-thienylacetoxy]propyl}-2-methyl-1H-imidazol-3-ium bromide (Compound No. 82);
1-{3-[2-Hydroxy(phenyl)-2-thienylacetoxy]propyl}-2,3-dimethyl-1H-imidazol-3-ium bromide (Compound No. 83);
1-[2-({(2R)-2-[(1R)-3,3-Difluorocyclopentyl]-2-hydroxy-2-phenylacetyl}oxy)ethyl]-2-methyl-3-(3-phenoxypropyl)-1H-imidazol-3-ium bromide (Compound No. 84);
3-(Cyclopropylmethyl)-1-[2-({(2R)-2-[(1R)-3,3-difluorocyclopentyl]-2-hydroxy-2-phenylacetyl}oxy)ethyl]-2-methyl-1H-imidazol-3-ium bromide (Compound No. 85);
3-Butyl-1-[2-({(2R)-2-[(1R)-3,3-difluorocyclopentyl]-2-hydroxy-2-phenylacetyl}oxy)ethyl]-2-methyl-1H-imidazol-3-ium bromide (Compound No. 86);
1-[2-({(2R)-2-[(1R)-3,3-Difluorocyclopentyl]-2-hydroxy-2-phenylacetyl}oxy)ethyl]-2-methyl-3-propyl-1H-imidazol-3-ium bromide (Compound No. 87);
1-[2-({(2R)-2-[(1R)-3,3-Difluorocyclopentyl]-2-hydroxy-2-phenylacetyl}oxy)ethyl]-3-ethyl-2-methyl-1H-imidazol-3-ium bromide (Compound No. 88);
3-Benzyl-1-{2-[2-hydroxy(di-2-thienyl)acetoxy]ethyl}-2-methyl-1H-imidazol-3-ium bromide (Compound No. 89);
3-(Cyclopropylmethyl)-1-{2-[2-hydroxy(di-2-thienyl)acetoxy]ethyl}-2-methyl-1H-imidazol-3-ium bromide (Compound No. 90);
3-Ethyl-1-{2-[2-hydroxy(di-2-thienyl)acetoxy]ethyl}-2-methyl-1H-imidazol-3-ium bromide (Compound No. 91);
1-{2-[2-Hydroxy(di-2-thienyl)acetoxy]ethyl}-2,3-dimethyl-1H-imidazol-3-ium bromide (Compound No. 92);
1-{3-[2-Hydroxy(di-2-thienyl)acetoxy]propyl}-2-methyl-3-(2-phenylethyl)-1H-imidazol-3-ium bromide (Compound No. 93);
1-{3-[2-Hydroxy(di-2-thienyl)acetoxy]propyl}-2-methyl-3-(3-phenoxypropyl)-1H-imidazol-3-ium bromide (Compound No. 94);
3-Butyl-1-{3-[2-hydroxy(di-2-thienyl)acetoxy]propyl}-2-methyl-1H-imidazol-3-ium bromide (Compound No. 95);
3-Ethyl-1-{3-[2-hydroxy(di-2-thienyl)acetoxy]propyl}-2-methyl-1H-imidazol-3-ium bromide (Compound No. 96);
1-{3-[2-Hydroxy(di-2-thienyl)acetoxy]propyl}-2,3-dimethyl-1H-imidazol-3-ium bromide (Compound No. 97);
1-(3-{[(2R)-2-Hydroxy-2-phenyl-2-{(1S)-3-[(phenylsulfonyl)amino]cyclopentyl}acetyl]oxy}propyl)-2,3-dimethyl-1H-imidazol-3-ium bromide (Compound No. 98);
3-Benzyl-1-(3-{[(2R)-2-hydroxy-2-phenyl-2-{(1S)-3-[(phenylsulfonyl)amino]cyclopentyl}acetyl]oxy}propyl)-2-methyl-1H-imidazol-3-ium bromide (Compound No. 99);
3-(4-Bromobenzyl)-1-(3-{[(2R)-2-hydroxy-2-phenyl-2-{(1S)-3-[(phenylsulfonyl) amino]cyclopentyl}acetyl]oxy}propyl)-2-methyl-1H-imidazol-3-ium bromide (Compound No. 100);
1-[3-({(2R)-2-[(1S)-3,3-Difluorocyclopentyl]-2-hydroxy-2-phenylacetyl}oxy)propyl]-3-ethyl-2-methyl-1H-imidazol-3-ium bromide (Compound No. 101);
1-[3-({(2R)-2-[(1S)-3,3-Difluorocyclopentyl]-2-hydroxy-2-phenylacetyl}oxy)propyl]-2-methyl-3-propyl-1H-imidazol-3-ium bromide (Compound No. 102);
3-Butyl-1-[3-({(2R)-2-[(1S)-3,3-difluorocyclopentyl]-2-hydroxy-2-phenylacetyl}oxy)propyl]-2-methyl-1H-imidazol-3-ium bromide (Compound No. 103);
1-[3-({(2R)-2-[(1S)-3,3-Difluorocyclopentyl]-2-hydroxy-2-phenylacetyl}oxy)propyl]-2-methyl-3-pentyl-1H-imidazol-3-ium bromide (Compound No. 104);
1-[3-({(2R)-2-[(1S)-3,3-Difluorocyclohexyl]-2-hydroxy-2-phenylacetyl}oxy)propyl]-3-ethyl-2-methyl-1H-imidazol-3-ium bromide (Compound No. 105);
1-[3-({(2R)-2-[(1S)-3,3-Difluorocyclohexyl]-2-hydroxy-2-phenylacetyl}oxy)propyl]-2-methyl-3-propyl-1H-imidazol-3-ium bromide (Compound No. 106);
1-[3-({(2R)-2-[(1S)-3,3-Difluorocyclohexyl]-2-hydroxy-2-phenylacetyl}oxy)propyl]-3-(1-ethylpropyl)-2-methyl-1H-imidazol-3-ium bromide (Compound No. 107);
1-[3-({(2R)-2-[(1S)-3,3-Difluorocyclohexyl]-2-hydroxy-2-phenylacetyl}oxy)propyl]-3-isopropyl-2-methyl-1H-imidazol-3-ium bromide (Compound No. 108);
1-[3-({(2R)-2-[(1S)-3,3-Difluorocyclohexyl]-2-hydroxy-2-phenylacetyl}oxy)propyl]-2-methyl-3-pentyl-1H-imidazol-3-ium bromide (Compound No. 109);
1-[3-({(2R)-2-[(1S)-3,3-Difluorocyclopentyl]-2-hydroxy-2-phenylacetyl}oxy)propyl]-3-isobutyl-2-methyl-1H-imidazol-3-ium bromide (Compound No. 110);
1-[3-({(2R)-2-[(1S)-3,3-Difluorocyclopentyl]-2-hydroxy-2-phenylacetyl}oxy)propyl]-3-(1-ethylpropyl)-2-methyl-1H-imidazol-3-ium bromide (Compound No. 111);
1-[3-({(2R)-2-[(1S)-3,3-Difluorocyclopentyl]-2-hydroxy-2-phenylacetyl}oxy)propyl]-3-isopropyl-2-methyl-1H-imidazol-3-ium bromide (Compound No. 112);
3-Butyl-1-[3-({(2R)-2-[(1S)-3,3-difluorocyclohexyl]-2-hydroxy-2-phenylacetyl}oxy)propyl]-2-methyl-1H-imidazol-3-ium bromide (Compound No. 113);
1-[2-({(2R)-2-[(1S)-3,3-Difluorocyclohexyl]-2-hydroxy-2-phenylacetyl}oxy)ethyl]-3-(1-ethylpropyl)-2-methyl-1H-imidazol-3-ium bromide (Compound No. 114);
1-[2-({(2R)-2-[(1S)-3,3-Difluorocyclohexyl]-2-hydroxy-2-phenylacetyl}oxy)ethyl]-2-methyl-3-pentyl-1H-imidazol-3-ium bromide (Compound No. 115);
3-Butyl-1-[2-({(2R)-2-[(1S)-3,3-difluorocyclohexyl]-2-hydroxy-2-phenylacetyl}oxy)ethyl]-2-methyl-1H-imidazol-3-ium bromide (Compound No. 116);
1-[2-({(2R)-2-[(1S)-3,3-Difluorocyclohexyl]-2-hydroxy-2-phenylacetyl}oxy)ethyl]-2-methyl-3-propyl-1H-imidazol-3-ium bromide (Compound No. 117);
1-[2-({(2R)-2-[(1S)-3,3-Difluorocyclohexyl]-2-hydroxy-2-phenylacetyl}oxy)ethyl]-3-ethyl-2-methyl-1H-imidazol-3-ium bromide (Compound No. 118);
1-[2-({(2R)-2-[(1S)-3,3-Difluorocyclohexyl]-2-hydroxy-2-phenylacetyl}oxy)ethyl]-2,3-dimethyl-1H-imidazol-3-ium bromide (Compound No. 119);
1-[2-({(2R)-2-[(1S)-3,3-Difluorocyclopentyl]-2-hydroxy-2-phenylacetyl}oxy)ethyl]-3-(1-ethylpropyl)-2-methyl-1H-imidazol-3-ium bromide (Compound No. 120);
1-[2-({(2R)-2-[(1S)-3,3-Difluorocyclopentyl]-2-hydroxy-2-phenylacetyl}oxy)ethyl]-3-isopropyl-2-methyl-1H-imidazol-3-ium bromide (Compound No. 121);
1-[2-({(2R)-2-[(1S)-3,3-Difluorocyclopentyl]-2-hydroxy-2-phenylacetyl}oxy)ethyl]-2-methyl-3-pentyl-1H-imidazol-3-ium bromide (Compound No. 122);
3-Butyl-1-[2-({(2R)-2-[(1S)-3,3-difluorocyclopentyl]-2-hydroxy-2-phenylacetyl}oxy)ethyl]-2-methyl-1H-imidazol-3-ium bromide (Compound No. 123);
1-[2-({(2R)-2-[(1S)-3,3-Difluorocyclopentyl]-2-hydroxy-2-phenylacetyl}oxy)ethyl]-2-methyl-3-propyl-1H-imidazol-3-ium bromide (Compound No. 124);
1-[2-({(2R)-2-[(1S)-3,3-Difluorocyclopentyl]-2-hydroxy-2-phenylacetyl}oxy)ethyl]-3-ethyl-2-methyl-1H-imidazol-3-ium bromide (Compound No. 125);
2-(2-Methyl-1H-imidazol-1-yl)ethyl (2R)-[(1R)-3,3-difluorocyclohexyl](hydroxy)phenylacetate (Compound No. 126);
3-(2-Methyl-1H-imidazol-1-yl)propyl (2R)-[(1R)-3,3-difluorocyclohexyl](hydroxy)phenylacetate (Compound No. 127);
3-(2-Methyl-1H-imidazol-1-yl)propyl cycloheptyl(hydroxy)phenylacetate (Compound No. 128);
2-(2-Methyl-1H-imidazol-1-yl)ethyl (2R)-[(1S)-3,3-difluorocyclohexyl](hydroxy)phenylacetate (Compound No. 129);
4-(2-Methyl-1H-imidazol-1-yl)butyl (2R)-[(1R)-3,3-difluorocyclopentyl](hydroxy)phenylacetate (Compound No. 130);
4-(2-Methyl-1H-imidazol-1-yl)butyl (2R)-[(1R)-3,3-difluorocyclohexyl](hydroxy)phenylacetate (Compound No. 131);
2-(2-Methyl-1H-imidazol-1-yl)ethyl hydroxy(phenyl)-2-thienylacetate (Compound No. 132);
2-(2-Methyl-1H-imidazol-1-yl)ethyl hydroxy[bis(3-methylphenyl)]acetate (Compound No. 133);
2-(2-Methyl-1H-imidazol-1-yl)ethyl bis(4-fluorophenyl)(hydroxy)acetate (Compound No. 134);
3-(2-Methyl-1H-imidazol-1-yl)propyl bis(4-fluorophenyl)(hydroxy)acetate (Compound No. 135);
3-(2-Methyl-1H-imidazol-1-yl)propyl hydroxy[bis(3-methylphenyl)]acetate (Compound No. 136);
3-(2-Methyl-1H-imidazol-1-yl)propyl hydroxy(phenyl)2-thienylacetate (Compound No. 137);
2-(2-Methyl-1H-imidazol-1-yl)ethyl hydroxy(di-2-thienyl)acetate (Compound No. 138);
3-(2-Methyl-1H-imidazol-1-yl)propyl hydroxy(di-2-thienyl)acetate (Compound No. 139);
3-(2-Methyl-1H-imidazol-1-yl)propyl (2R)-hydroxy(phenyl){(1S)-3-[phenylsulfonyl)amino]cyclopentyl}acetate (Compound No. 140); and
3-(2-Methyl-1H-imidazol-1-yl)propyl (2R)-[(1S)-3,3-difluorocyclohexyl](hydroxy)phenylacetate (Compound No. 141).

### Claim 3 (depends on 1, 2)

A pharmaceutical composition comprising a therapeutically effective amount of a compound as defined in claim 1 or 2 together with pharmaceutically acceptable carriers, excipients or diluents.

### Claim 4 (depends on 1, 2)

The use of compounds according to claim 1 or 2 for the manufacture of medicament for treating or preventing disorder of the respiratory, urinary and gastrointestinal systems, wherein the disease or disorder is mediated through muscarinic receptors, in animal or human.

### Claim 5 (depends on 4)

The use of the compounds as described in claim 4 for the manufacture of medicament for treating or preventing urinary incontinence, lower urinary tract symptoms (LUTS), bronchial asthma, chronic obstructive pulmonary disorders (COPD), pulmonary fibrosis, irritable bowel syndrome, obesity, diabetes or gastrointestinal hyperkinesis.

### Claim 6 (depends on 3)

The use of the compounds as defined in claim 3 for the manufacture of a medicament for the treating or preventing disease or disorder of the respiratory, urinary and gastroinstestinal systems, wherein the disease or disorder is mediated through muscarinic receptors, in animal or human.

### Claim 7 (depends on 6)

The use of the compounds as defined in claim 6 for the manufacture of a medicament for the treating or preventing urinary incontinence, lower urinary tract symptoms (LUTS), bronchial asthma, chronic obstructive pulmonary disorders (COPD), pulmonary fibrosis, irritable bowel syndrome, obesity, diabetes or gastrointestinal hyperkinesis.

### Claim 8

A pharmaceutical composition comprising one or more compounds of Formula I
and its pharmaceutically accepted salts, pharmaceutically acceptable solvates, enantiomers, diastereomers, polymorphs or N-oxides wherein
represents a single bond when G is —OH and double bond when G is —O;
R1 and R2 are independently selected from hydrogen, alkyl, alkenyl, alkynyl, aralkyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, heterocyclylalkyl or heteroarylalkyl;
R3 is selected from the group selected from hydrogen, hydroxy, alkoxy, alkenyloxy or alkynyloxy;
X is selected from oxygen, —NH, —NR (wherein R is alkyl, alkenyl, alkenyl, alkynyl or aryl), sulphur or no atom;
Het is heterocyclyl or heteroaryl;
n is an integer from 1 to 6;
with the proviso that when R1 and R2 are phenyl, R3 is hydroxy and X is no atom then Het cannot be a saturated heterocyclyl group
and at least one other active ingredients selected from corticosteroids, beta agonists, leukotriene antagonists, 5-lipoxygenase inhibitors, anti-histamines, antitussives, dopamine receptor antagonists, chemokine inhibitors, p38 MAP Kinase inhibitors, and PDE-IV inhibitors

### Claim 9

A method of making compounds of Formula IVa, and its pharmaceutically acceptable salts, pharmaceutically acceptable solvates, enantiomers, diastereomers, polymorphs or N-oxides
wherein the method comprises:
a. coupling a compound of Formula II
with a compound of formula III
to give a compound of Formula IV
b) reacting a compound of Formula IV with a compound of Formula Q-Z to give a compound of Formula IVa
wherein
R1 and R2 are independently selected from hydrogen, alkyl, alkenyl, alkynyl, aralkyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, heterocyclylalkyl or heteroarylalkyl;
R3 is selected from the group selected from hydrogen, hydroxy, alkoxy, alkenyloxy or alkynyloxy;
X is selected from oxygen, —NH, —NR (wherein R is alkyl, alkenyl, alkenyl, alkynyl or aryl), sulphur or no atom;
n is an integer from 1 to 6;
R1′ is selected from hydrogen, alkyl, alkenyl, alkynyl, aralkyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, heterocyclylalkyl or heteroarylalkyl and R1′ is always a substitutent on the carbon atoms of imidazolyl ring;
Q is selected from alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, aralkyl, heteroarylalkyl or heterocyclylalkyl;
Z is an anion selected from tartarate, chloride, bromide, iodide, sulphate, phosphate, nitrate, carbonate, fumarate, glutamate, citrate, methanesulphonate, benzenesulphonate, maleate or succinate;
